ArticleOpen medicine (Warsaw, Poland)2026
Immunoinformatics and molecular modeling approaches to design a multi-epitope vaccine against Tibrovirus Congo.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The objective of this study was to design and evaluate a computationally optimized multi-epitope vaccine targeting the G protein and nucleoprotein of Tibrovirus Congo using immunoinformatics and molecular simulation approaches. Methods: B-cell and T-cell epitopes were predicted, screened for antigenicity, allergenicity, and toxicity, and linked with GPGPG, AAY, and KK linkers. A β-defensin-3 adjuvant and a PADRE sequence were incorporated, generating a 224-amino acid vaccine construct. Population coverage was analyzed globally. The tertiary structure was modeled, refined, and validated using Ramachandran plot analysis and ERRAT scoring. Molecular docking was performed with TLR2 and TLR4 receptors, followed by 100 ns molecular dynamics (MD) simulations. Root mean square deviation (RMSD), root mean square fluctuations (RMSF),radius of gyration, dynamic cross-correlation matrix (DCCM), principal component analysis (PCA), and free energy landscape (FEL) analyses were applied to assess stability and motion. Results: The vaccine construct was predicted to be highly antigenic, non-allergenic, and stable, with 91.81 % global population coverage, highest in Europe and North America. The refined 3D model achieved a Ramachandran favored-region score of 96.3 % and an ERRAT score of 99.63. Docking revealed strong affinity toward TLR2 (-1,665.5, 16 hydrogen bonds) compared to TLR4 (-1,227.8). MD simulations confirmed stable binding, with an average RMSD of 6 Å, a radius of gyration of around 19.8 Å, and RMSF between 1 and 4 Å. DCCM and PCA indicated positive residue correlations and stable conformational dynamics. Immune simulations predicted robust humoral and cellular responses, including elevated IgG, IgM, IL-2, and IFN-γ levels, and long-term memory cell formation. Conclusions: The designed vaccine construct demonstrates promising immunogenic and structural properties, suggesting potential efficacy against Tibrovirus Congo. Further
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.